Nuwellis, Inc. (NUWE) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-03-11

How it makes money

It earns by selling Aquadex systems to treat fluid overload when loop diuretics fail, with 40% of 2025 revenue from pediatric care.

Hospitals pay for the Aquadex System because between 10% and 40% of heart failure patients are refractory to loop diuretics. While the system removes excess salt and water through ultrafiltration (aquapheresis), its portable design allows it to be prescribed by any physician rather than just a nephrologist.

Revenue is driven by a razor-and-blade model: the initial sale of consoles leads to recurring high-margin sales of single-use disposable blood circuits and catheters required for every treatment. Clinical categories include pediatrics (40%), critical care (32%), and heart failure (17%).

What protects it: the moat

Its system does not require a nephrologist for administration and operates with an extracorporeal blood volume of only 35 ml.

The company maintains a competitive advantage over standard dialysis machines, like the Baxter HF20, which require a much higher 58 ml blood volume. This lower volume allows for use in smaller patients and utilizes simpler peripheral or central venous access.

Clinical evidence further protects its market share; studies show Aquadex results in 1.74 fewer heart failure rehospitalizations per year compared to traditional medical management. Management claims the system is easier to integrate into general cardiology units without needing specialized renal care staff.

What growth costs

It is developing a dedicated pediatric device, Vivian, for patients weighing 2.5 kg, while saving $4.0 million by terminating the REVERSE-HF heart failure study.

The company is transitioning its capital structure by outsourcing all assembly of consoles and circuits to KDI Precision Manufacturing to streamline operations. To prioritize this shift, it terminated its REVERSE-HF clinical trial in 2025 to reallocate resources toward outpatient and pediatric growth.

Significant investment is now directed toward 'Vivian,' a dedicated renal replacement device for infants weighing between 2.5 kg and 20 kg, supported by a $3 million NIH grant.

What could damage it

It faces a total cessation of operations by mid-2026 if it cannot secure new funding to offset its $316.3 million accumulated deficit.

The company suffers from a critical liquidity shortage, with current capital only expected to fund operations through the second quarter of 2026. Because its prospects are tied to a single product line, any failure to raise additional capital would permanently impair its ability to manufacture components and fulfill hospital orders.

Material weaknesses in internal controls, specifically regarding inadequate headcount for financial reporting, increase the risk of misstatements that could further restrict its access to capital markets.

About Nuwellis, Inc.

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Other companies in Medical Devices